- cafead Aug 14, 2024 at 10:53: PM
via After Arrowhead Pharmaceuticals cleared out its work on a clinical-stage cardiovascular candidate, the company is filling the blank space with two obesity assets, both set to enter the clinic in early 2025.
The RNA interference (RNAi) company presented two next-gen candidates during an R&D investor event Aug. 14: Dubbed ARO-INHBE and ARO-ALK7, they are designed to treat obesity and metabolic diseases.
article source
The RNA interference (RNAi) company presented two next-gen candidates during an R&D investor event Aug. 14: Dubbed ARO-INHBE and ARO-ALK7, they are designed to treat obesity and metabolic diseases.
article source